BRD4 degradation was found to reduce PD-L1 upregulation on CML LSCs, which is attributed to both inhibition of IFN-γ-mediated upregulation and because the PDL1 gene is a target of BRD4 [82]. The gene discussed is BRD4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.